Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interpretable Multimodal Artificial Intelligence Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces

NCT07820423 is registered in ClinicalTrials.gov with Central South University as lead sponsor.

NCT NCT07820423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07820423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interpretable Multimodal Artificial Intelligence Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
Lead sponsor
Central South University
Phase
Observational
Overall status
Recruiting
Start date
May 1, 2025
Completion date
December 31, 2026
Enrollment
600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer associated with cystic airspaces